ABBOTT PARK, Illinois, December 8, 2011 -
DES PLAINES, Illinois, November 28, 2011 -
ABBOTT PARK, Illinois, November 14, 2011 -
ABBOTT PARK, Illinois, November 7, 2011 -
More News
- Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
- Abbott Honored With Scrip Award for Leadership in Corporate Social Responsibility
- Abbott to Present New Data for Key Vascular Products at TCT 2011
- Experts Report that Abbott’s New PLEX-ID Assay Offers Important Testing Capabilities for Biothreat Defense
- Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
- Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent
- Abbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2011
- Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Abbott’s ABSORB™ Bioresorbable Vascular Scaffold Honored with Wall Street Journal Technology Innovation Award
- Abbott Enrolls First U.S. Patient in Global EXCEL Trial Comparing XIENCE to Coronary Artery Bypass Surgery
- Abbott Announces Availability of Two New CE-Marked Molecular Assays for its m2000 System to Detect Infections Spread in Healthcare Settings
- Abbott Named Top Dealmaker for Fourth Consecutive Year by The Deal
- Abbott Declares 351st Consecutive Quarterly Dividend
- Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
- Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer
- Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
- First Patient in Japan Treated with Abbott’s Bioresorbable Vascular Scaffold as Part of Global Clinical Trial
- Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market
- Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range
- Abbott Confirms Long-Term Commitment to HIV Care with the Planned Development of New Formulations
- Abbott to Fund Pharmaceutical and Diagnostics Research at the Weizmann Institute of Science
- New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
- Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
- Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Abbott Declares 350th Consecutive Quarterly Dividend
- Abbott Receives CE Mark for its RealTime Molecular Test for Cytomegalovirus
- Abbott Receives U.S. FDA Approval for XIENCE nano(TM) to Treat Coronary Artery Disease in Small Vessels
- Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay
- Abbott's Labs Are Vital(TM) Honors University of Sheffield Team for Outstanding Research
- Abbott Features Novel Biomarkers and Laboratory Automation at International Federation of Clinical Chemistry Congress
- Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Receives CE Mark
- Abbott Receives FDA Approval to Expand Use of the RX ACCULINK(R) Carotid Stent System to Patients at Standard Surgical Risk
- Abbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting
- Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter
- Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
- Data From Landmark Clinical Trial of Abbott's MitraClip(R) System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment
- Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V(R)
- Abbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results
- Abbott Introduces Hepatitis B Sequencing Test in Europe
- Abbott Announces Crohn's Disease Trial to Explore Benefit of New Therapeutic Monitoring Parameters for Patients
- Abbott Announces Launch of Catheter-Based MitraClip(R) System in Australia for Mitral Regurgitation, the Most Common Heart Valve Condition
- Abbott to Present Data on Novel Vascular Technologies and XIENCE V(R) at ACC 2011
- Abbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults
- Abbott Supports Relief Efforts in Japan
- Abbott Launches a CE Marked KIF6 Test in Europe
- Abbott Announces Increase in Quarterly Dividend
- Abbott's TREK(R) Coronary Balloon System Now Available in the United States and Japan
- Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011
- FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk
- New Abbott Vitamin D Test Available for Use in the European Union
- Study Suggests Urine NGAL Biomarker May Help Predict Delayed Graft Function
- Abbott's XIENCE PRIME(TM) Receives CE Mark for Treatment of Most Advanced Form of Arterial Disease in the Lower Leg
- Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
- EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
- Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
- Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA
- Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
- Abbott Wins Two Scrip Awards Recognizing Excellence in Pharmaceutical and Biotech Industries
- Abbott Reports Strong Third Quarter Results; Confirms Double-Digit Ongoing Earnings Outlook for 2010
- Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)
- Abbott's Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
- Abbott to Present Data on Market-Leading XIENCE V(R) and Promising Vascular Pipeline at TCT 2010
- Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance
- Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2010
- Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
- Abbott Announces European Launch of TREK(TM) Catheter System, Representing an Advancement in Balloon Technology
- The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbott's Carotid Stent System and Surgery
- Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
- New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent
- Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
- Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business
- Abbott Honored as a Great Place to Work Across Europe
- Abbott to Present New Clinical Data on Current and Future Innovations in Interventional Cardiology at EuroPCR 2010
- Abbott Introduces New, Easier-to-Use and More Accurate Line of FreeStyle Test Strips in Europe
- Abbott Accelerates Emerging Markets Pharmaceutical Leadership With Zydus Cadila Collaboration; Separately Creates Stand-Alone Established Products Division
- The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
- Abbott Completes Acquisition of Facet Biotech
- Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
- New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
- Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
- Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
- Abbott Completes Acquisition of Solvay Pharmaceuticals
- Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
- Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
- New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark
- Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
- Abbott’s XIENCE PRIME(TM) and XIENCE V(R) Receive Indications in Europe for Treatment of Patients with Diabetes
- Abbott to Acquire Solvay Pharmaceuticals Business
- Results from Abbott’s PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
- Abbott’s XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
- Abbott’s XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
- Abbott’s XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
- Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
- Abbott Receives CE Mark for Company’s Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
